SCHEMBL1005593

SCHEMBL1005593

CC(CO)NCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.68
POLB P06746 2/20 0.53
MAPK1 P28482 1/20 0.49
TRPA1 O75762 1/20 0.48
BCHE P06276 1/20 0.47
GAA P10253 1/20 0.47
ATM Q13315 1/20 0.47
THRB P10828 1/20 0.46
IDO1 P14902 1/20 0.46
LMNA P02545 1/20 0.46
TAAR1 Q96RJ0 2/20 0.45
SLC18A2 Q05940 1/20 0.45
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP3A4 P08684 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
ACP3 P15309 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1189292 1.00 SIGMAR1 (0.68) SIGMAR1POLBMAPK1TRPA1BCHE
SCHEMBL1005591 1.00 SIGMAR1 (0.68) SIGMAR1POLBMAPK1TRPA1BCHE
SCHEMBL1752567 0.89 SIGMAR1 (0.59) SIGMAR1POLBMAPK1BCHELMNA
SCHEMBL31127843 0.84 SIGMAR1 (0.63) SIGMAR1POLBMAPK1BCHEGAA
SCHEMBL536907 0.84 SIGMAR1 (0.63) SIGMAR1POLBMAPK1BCHEGAA
N-Benzylamphetamine SCHEMBL2451256 0.81 SIGMAR1 (1.00) SIGMAR1POLBMAPK1LMNATAAR1
SCHEMBL172633 0.81 SIGMAR1 (0.70) SIGMAR1POLBMAPK1BCHELMNA
N-Benzylamphetamine SCHEMBL2795222 0.81 SIGMAR1 (1.00) SIGMAR1POLBMAPK1LMNATAAR1
N-Benzylamphetamine SCHEMBL2798189 0.81 SIGMAR1 (1.00) SIGMAR1POLBMAPK1LMNATAAR1
SCHEMBL13675825 0.81 SIGMAR1 (0.70) SIGMAR1POLBMAPK1BCHELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112218849-B Process for the preparation of amines 巴斯夫欧洲公司 2023-08-18 CN claimed
US-11390578-B2 Method for synthesizing amines BASF SE (DE) 2022-07-19 US claimed
EP-3774716-B1 PROCESS FOR THE PREPARATION OF AMINES BASF SE (DE) 2022-03-16 EP claimed
US-20210155574-A1 METHOD FOR SYNTHESIZING AMINES BASF SE (DE) 2021-05-27 US claimed
EP-3774716-A1 METHOD FOR SYNTHESIZING AMINES BASF SE (DE) 2021-02-17 EP claimed
CN-112218849-A Process for preparing amines 巴斯夫欧洲公司 2021-01-12 CN claimed
WO-2019192903-A1 METHOD FOR SYNTHESIZING AMINES BASF SE (DE) 2019-10-10 WO claimed
EP-0301925-B1 PROCESS FOR THE ENANTIOSPECIFIC PREPARATION OF (S)2-ETHYL AMINO-1-3-(TRIFLUOROMETHYL PHENYL) PROPANE ADIR ET COMPAGNIE (FR) 1991-10-23 EP claimed
EP-3560932-B1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES OF SAME JAPAN TOBACCO INC (JP) 2026-03-11 EP disclosed
US-12319679-B2 Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2025-06-03 US disclosed
US-20250084106-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF LEO PHARMA A/S (DK) 2025-03-13 US disclosed
US-20250066313-A1 Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein BEONE MEDICINES I GMBH (CH) 2025-02-27 US disclosed
US-12195481-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof JAPAN TOBACCO INC. (JP) 2025-01-14 US disclosed
CN-118317943-A Synthesis method of chiral 3, 5-disubstituted morpholine compound and useful intermediate thereof 百济神州有限公司 2024-07-09 CN disclosed
EP-0044984-A1 Process for the optical resolution of mixtures of d- and l-2-(6-methoxy-2-naphthyl)-propionic acids, the cinchonidine salt of d-2-(6-methoxy-2-naphthyl)-propionic acid and the preparation thereof ALFA FARMACEUTICI S.p.A. (IT) 1982-02-03 EP disclosed
US-4247498-A THERMOPLASTICS AKZONA INCORPORATED (US) 1981-01-27 US disclosed
US-4246164-A SALT FORMATION WITH N-METHYL-D-GLUCAMINE SYNTEX CORPORATION (PA) 1981-01-20 US disclosed
US-4239912-A SALT FORMATION AMERICAN CYANAMID COMPANY (US) 1980-12-16 US disclosed
EP-0007116-A1 Method for resolving racemic 6-methoxy-alpha-methyl-2-naphthalene acetic acid into its enantiomers and resolving medium SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1980-01-23 EP disclosed
US-3998827-A HYPOTENSIVE AGENTS THE UPJOHN COMPANY (US) 1976-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11390578-B2 Method for synthesizing amines PNMT, ADH1A, ADH1C SIGMAR1 1209/4885POLB 731/4885MAPK1 2036/4885
US-12319679-B2 Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors MAN2A1, MAN2B2, MGAT3 SIGMAR1 2022/4885POLB 3038/4885MAPK1 2547/4885
US-12195481-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof JAK1, JAK3, JAK2 SIGMAR1 1347/4885POLB 509/4885MAPK1 73/4885
US-20210155574-A1 METHOD FOR SYNTHESIZING AMINES PNMT, ADH1A, ADH1C SIGMAR1 1209/4885POLB 731/4885MAPK1 2036/4885
US-20250084106-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF JAK1, JAK3, JAK2 SIGMAR1 1347/4885POLB 509/4885MAPK1 73/4885
US-20250066313-A1 Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein BAD, BID, AIFM1 SIGMAR1 2275/4885POLB 322/4885MAPK1 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.